Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

CEO Stéphane Bancel laid out a plan to reverse that. Moderna CEO Stéphane Bancel said in his 2024 shareholder letter published Monday that the past year brought "formidable challenges" for the ...

Ahead of CEO Stéphane Bancel’s address at the JP Morgan Healthcare Conference 2025, being held in San Francisco, the company announced business and pipeline updates that emphasised the company ...

One of the closest-to-market among the 10 is mRNA-1283, a next-generation COVID vaccine. In his Monday letter, Bancel said the FDA has accepted Moderna’s application for the shot. Assisted by a ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

It expects to end 2025 with a cash balance of $6 billion. Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and ...